Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on KROMEK GROUP PLC. We currently have 8 research reports from 2 professional analysts.
|24Nov16 02:15||RNS||Holding(s) in Company|
|18Nov16 12:15||RNS||Notice of Results|
|02Nov16 07:00||RNS||New BMD orders from existing OEM customers|
|19Oct16 07:00||RNS||Delivery of 10,000 units of D3S to DARPA|
|17Oct16 07:00||RNS||Six New Contract Wins Across All Business Segments|
|30Sep16 12:22||RNS||Block listing Interim Review|
|21Sep16 12:33||RNS||Result of AGM|
Frequency of research reports
Research reports on
KROMEK GROUP PLC
KROMEK GROUP PLC
Substantial new military opportunity
19 Oct 16
When is the right time to buy high growth smallcaps? Some investors would advise caution due to the risks, yet this is exactly the type of situation that can produce lucrative returns. For us the trick is to identify undervalued stocks that are not only winning new and repeat business – ie a sure-fire sign that customers like what they see – but also the size of their addressable markets is expanding.
Protecting the US public against ‘dirty bombs’
22 Feb 16
After last week’s deadly terrorist attack in the Turkish capital of Ankara, along with the horrific shootings in Paris and the downing of a Russian airplane in Syria, Western governments are once again on red alert. Worse still, there is now an increasing concern that these atrocities could go nuclear, as Islamic State (ISIS) may have recently acquired enough “highly dangerous" radioactive material from a Syrian warehouse, in order to create a ‘dirty bomb’
Backlog up 19% after $7m of new orders
16 Dec 15
If you were lucky enough to be an early investor in Facebook, Uber or Google, then you’ll be well versed in the concept of “disruptive technologies”. Game-changing new inventions though are not the sole preserve of Silicon Valley. Spend a few hours strolling around Kromek’s equally innovative R&D/manufacturing facilities in the UK/US, and you’ll understand why its revolutionary new cadmium zinc telluride (CZT) products could soon change the face of the global medical imaging, homeland security and nuclear detection markets.
30 Nov 16
Abzena (ABZA): Interim results indicate happy customers (BUY) | Horizonte Minerals* (HZM): Fund raise completed (CORP) | SacOil* (SAC): Half-year trading statement (CORP) | Revolution Bars (RBG): New openings (BUY) | Amino Technologies* (AMO): Multi operator FUSION roll out (CORP)
N+1 Singer - Morning Song 30-11-2016
30 Nov 16
Sanderson has delivered full year results in line with expectations and the 19 October trading update after a strong finish to the year compensated for a slower start. A healthy level of pre-contracted recurring revenue (50%), incremental sales to existing customers and new customer wins at higher average order values helped deliver solid revenue growth in both the Digital Retail (+9%) and Enterprise (+12%) divisions. A decent order book and good sales momentum suggest that the company is on track to deliver on unchanged profit expectations for the current year. We continue to view the valuation (FY17 EV/EBITDA 8.6x) as undemanding given an attractive combination of accelerating growth potential, strong cash generation and growing dividends.
N+1 Singer - Morning Song 29-11-2016
29 Nov 16
Vp has reported another impressive set of interims, confirming strong growth in most markets and a positive outlook. Recent acquisitions are bedding in well and the full year outturn is set to exceed previous expectations (5%/6% EPS upgrades in FY17/FY18). The recent Capital Markets Day provided a reminder of Vp’s qualities (specialist focus, high returns, strong cash generation) and its growth potential, which in our view are not reflected in a modest <11x P/E rating. We firmly believe the shares are due a re-rating and see intrinsic value in excess of 800p.
Food intolerance driving growth
29 Nov 16
Omega Diagnostics Group has an established core business providing high quality in vitro diagnostic tests within three core areas of competence – Food Intolerance, Allergy & Autoimmune, Infectious Disease – that are sold in over 100 countries. The group offers steady low single-digit growth which is profitable and cash generative. Investment in new products has seen the launch of a new panel of automated allergy tests and progress on Visitect CD4 for monitoring of HIV positive patients. Interim results highlighted the opportunities to accelerate growth of the business, particularly Allersys, which has drawn attention from its partner.
Small Cap Breakfast
29 Nov 16
Asia Pacific Investment Partner - the research-driven emerging and frontier markets real estate development business intends to float on AIM and conduct a placing in December RM Secured Direct Lending - The secured direct lending fund intends to float on the Main Market on 15 December raising up to £100m Diversified Oil & Gas— Schedule One now out. $60m to be raised. Expected admission 6 December. Creo Medical Group —UK based medical device company focused on surgical endoscopy, a recent development in minimally invasive surgery. Admission due 7 December. Fundraising details TBA.